BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37016537)

  • 1. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
    Yu D; Wang H; Liu H; Xu R
    J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer.
    Liu C; Qian X; Yu C; Xia X; Li J; Li Y; Xie Y; Gao G; Song Y; Zhang M; Xue H; Wang X; Sun H; Liu J; Deng W; Guo X
    Cancer Lett; 2024 Apr; 586():216642. PubMed ID: 38278470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.
    Hu M; Zhou M; Bao X; Pan D; Jiao M; Liu X; Li F; Li CY
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33290271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
    Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
    Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
    Lu G; Qiu Y; Su X
    Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
    Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
    Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway.
    Yang Y; Qi J; Hu J; Zhou Y; Zheng J; Deng W; Inam M; Guo J; Xie Y; Li Y; Xu C; Deng W; Chen W
    Cancer Lett; 2024 Apr; 588():216765. PubMed ID: 38408604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
    Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
    Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.
    Zhang Q; Green MD; Lang X; Lazarus J; Parsels JD; Wei S; Parsels LA; Shi J; Ramnath N; Wahl DR; Pasca di Magliano M; Frankel TL; Kryczek I; Lei YL; Lawrence TS; Zou W; Morgan MA
    Cancer Res; 2019 Aug; 79(15):3940-3951. PubMed ID: 31101760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.
    Xu R; Huang Y; Mai J; Zhang G; Guo X; Xia X; Koay EJ; Qin G; Erm DR; Li Q; Liu X; Ferrari M; Shen H
    Small; 2013 May; 9(9-10):1799-808. PubMed ID: 23293085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
    Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
    Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM Inhibition-Induced ISG15/IFI27/OASL Is Correlated with Immunotherapy Response and Inflamed Immunophenotype.
    Huang CH; Huang YC; Xu JK; Chen SY; Tseng LC; Huang JL; Lin CS
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
    Zhang S; Guo L; Zhang Z; Liu X; Chen W; Wei Y; Wang X; Wu Q
    Cancer; 2024 Apr; 130(S8):1415-1423. PubMed ID: 38079306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer.
    Wu Z; Zhu L; Mai J; Shen H; Xu R
    J Biomed Nanotechnol; 2021 Dec; 17(12):2351-2363. PubMed ID: 34974858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.